Clinical Trials Browser

Phase 2 × NIH × irofulven × Clear all

NCT00053365 2019-07-24

Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer

Phase 2 Completed

61 enrolled 10 charts

Carcinoma, Ovarian Epithelial

NCT00003390 2013-06-21

6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer

Phase 2 Completed

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00019552 2013-06-20

Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

Phase 2 Completed

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00062257 2013-05-15

Irofulven in Treating Patients With Recurrent or Metastatic Gastric Cancer

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT00003796 2013-02-11

Irofulven in Treating Patients With Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms, Breast Neoplasms, Male